Pan-Cancer Analysis

Pan Cancer T Appoints Dr. Rachel Abbott as Chief Scientific Officer

Retrieved on: 
Tuesday, January 17, 2023
Dark, University, Pan-Cancer Analysis, Erasmus, Immunotherapy, Aeris Naviter AN-2 Enara, Erasmus MC, CD55, Head, Ligand, Therapy, Patient, Laboratory, TCR, European, Doctor of Philosophy, Vaccine

ROTTERDAM, January 17, 2023 - Pan Cancer T B.V. , a biotech spin-off from Erasmus MC dedicated to the discovery and development of next-generation TCR-T therapies against solid tumors, today announced the appointment of Dr. Rachel Abbott as Chief Scientific Officer.

Key Points: 
  • ROTTERDAM, January 17, 2023 - Pan Cancer T B.V. , a biotech spin-off from Erasmus MC dedicated to the discovery and development of next-generation TCR-T therapies against solid tumors, today announced the appointment of Dr. Rachel Abbott as Chief Scientific Officer.
  • Prior to joining Pan Cancer T, Rachel Abbott had been Senior Director, Head of TCR Pipeline and Dark Antigen Research at Enara Bio from March 2021 to January 2023.
  • "We warmly welcome Rachel Abbott to our management team,” said Katrien Reynders-Frederix, CEO of Pan Cancer T. "Rachel has tremendous industry experience, including developing T cell therapies, leading scientific research teams and managing collaborations with big pharma and academic institutions.
  • "I am honored to take over the position as Pan Cancer T´s Chief Scientific Officer,” said Dr. Rachel Abbott.

Isomorphic Labs Announces First Phase of Management Team

Retrieved on: 
Thursday, May 12, 2022
Software, Research, Pharmaceutical, Technology, Infectious Diseases, Clinical Trials, Science, Biotechnology, Other Technology, FDA, Other Science, Health, People, Food, The People's Operator, Royal Society, Ontario Institute for Cancer Research, Heidelberg University, Nature, Compliance, Rising Production, University, University of Leicester, Sophia, Breast, Drug discovery, Amazon, Oxford Brookes University, Sophia Genetics, Machine learning, GPCR, Biology, EMBL, DeepMind, Pan-Cancer Analysis, Algorithm, Research, Biophysics, Technical Working Groups, Ribociclib, Mathematics, Royal, AlphaFold, RSC, Google, Chemistry, Doctor of Philosophy, Risk, Science, University of Cambridge, FDA, Toronto, GENETICS, Publication, Engineering, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Deep learning, Technical, Astex, GlaxoSmithKline, G protein-coupled receptor, Drug development, Drug, Protein folding, CEO, Pharmaceutical industry, Medical device, Management, Alphabet, AI

Isomorphic Labs, a subsidiary of Alphabet, today announced the first phase of its management team.

Key Points: 
  • Isomorphic Labs, a subsidiary of Alphabet, today announced the first phase of its management team.
  • Isomorphic Labs mission is to use AI and machine learning methods to accelerate and improve the drug discovery process.
  • The new leaders join founder and acting CEO Demis Hassabis, who is currently serving as CEO of both DeepMind and Isomorphic Labs.
  • Isomorphic Labs is a subsidiary of Alphabet that was launched from Alphabets DeepMind in 2021, with headquarters in London.

Twist Bioscience Reports First Quarter 2022 Financial Results

Retrieved on: 
Friday, February 4, 2022
Science, Biotechnology, Nanotechnology, Research, Pharmaceutical, Health, Technology, Genetics, Webcast, Growth, CEO, Private Securities Litigation Reform Act, DNA, Abcam, Risk, NASDAQ, General officer, SEC, Silicon, Development, Omicron, Delta, Liquid biopsy, Engineering, ESG, Genomics, Technology, Capital, Research, NGS, COVID-19, Capital expenditure, Doctor of Philosophy, Cancer, Nucleic acid thermodynamics, VHH, Twist Bioscience, SynBio, U.S. Securities and Exchange Commission, Gene, Drug discovery, Agriculture, Annual report, GPCR, Administration, Pan-Cancer Analysis, Acquisition, Investment, Severe acute respiratory syndrome coronavirus 2, Security (finance), Biology, Synthetic biology, Martek Biosciences Corporation, RNA, Antibody, Video game, Vaccine, Spice, Reinsurance, Coal, Fine chemical, Pharmaceutical industry

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the first quarter of fiscal 2022 ended December 31, 2021.

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the first quarter of fiscal 2022 ended December 31, 2021.
  • Revenue: Total revenues for the first quarter of fiscal 2022 were $42.0 million compared to $28.2 million for the first quarter of fiscal 2021.
  • Shipped products to approximately 1,800 customers in the first quarter of fiscal 2022, versus approximately 1,500 in the first quarter of fiscal 2021.
  • Shipped approximately 125,000 genes during the first quarter of fiscal 2022, compared with approximately 84,000 in the first quarter of fiscal 2021.

World Liquid Biopsy Market Report 2022: Testing has Many Potential Applications in Aspects of Clinical Oncology - ResearchAndMarkets.com

Retrieved on: 
Friday, January 14, 2022
Surgery, Health, Lung, Pan-Cancer Analysis, Time, Prostate, Liquid biopsy, CTC, Disease, Diagnosis, Type, Lithium, Medical imaging, Cancer, Breast, Ovary

The "The World Liquid Biopsy Market 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "The World Liquid Biopsy Market 2021" report has been added to ResearchAndMarkets.com's offering.
  • While tissue biopsies and imaging techniques remain the current standards of care in the diagnosis of solid tumors, they have risks and limitations and limitations, some of which can be overcome by the use of liquid biopsy in clinical oncology, as an alternative or complementary technique to the current standards of care.
  • This report contains up-to-date information and useful data points for business planning:
    Liquid Biopsy Market by Type of Cancer (Breast, Lung, Colorectal, Ovarian, Prostate, Pan-Cancer, Other Cancer)
    Selected Market-Available CTC-based Liquid Biopsy Tests, 2021
    Selected Liquid Biopsy Tests That Assess Multiple Analytes, 2021
    Liquid biopsy testing has many potential applications in aspects of clinical oncology, including:
    Alternative testing method when tissue biopsy is difficult/impossible, or when the primary site of metastatic disease is unknown
    Therapy personalization and monitoring - by molecular characterization of a patient's disease, clinicians can select the optimal course of therapy and monitor efficacy over time, as well as quickly react to adjust therapy should treatment resistance arise
    Disease monitoring - to observe disease progression, tumor evolution, residual disease, and early detection of recurrence

Twist Bioscience Launches Circulating Tumor DNA Reference Controls for Development of Liquid Biopsy Assays

Retrieved on: 
Tuesday, December 7, 2021
Technology, Research, Genetics, Nanotechnology, Biotechnology, Health, Pharmaceutical, Science, Oncology, U.S. Securities and Exchange Commission, Twist Bioscience, Engineering, Risk, Nucleic acid thermodynamics, SEC, Oncogene, Technology, Limiting factor, NGS, Security (finance), Disease, Liquid biopsy, Agriculture, Drug discovery, Martek Biosciences Corporation, Private Securities Litigation Reform Act, DNA, Synthetic biology, CEO, Pan-Cancer Analysis, Neoplasm, Cancer, GameChanger, SNV calling from NGS data, Lod, Molecular reference standards, Genomics, COVID-19, Silicon, NASDAQ, Biology, Annual report, Workflow, DdPCR, Dietary supplement, Medical imaging, Vaccine

Liquid biopsy tests, which rely on NGS-based circulating tumor DNA (ctDNA) analysis, are a promising and growing area in clinical oncology.

Key Points: 
  • Liquid biopsy tests, which rely on NGS-based circulating tumor DNA (ctDNA) analysis, are a promising and growing area in clinical oncology.
  • Liquid biopsy assays can accurately identify a single tumor variant in the presence of thousands of healthy cells.
  • Applying the right reference materials is essential to benchmark the complexity and biological content of DNA found in liquid biopsy samples for assay development and validation.
  • All of these features make the Twist ctDNA reference a high-quality standard for the ctDNA variants that cancer liquid biopsy assays are designed to detect.

Cellecta Introduces GeoMx Digital Spatial Profiling Service to Provide Novel Insights into Tumor Biology

Retrieved on: 
Thursday, November 5, 2020
Branches of biology, Omics, RNA, Biology, Gene expression, Molecular biology, Transcriptome, Transcriptomics technologies, Pan-Cancer Analysis

MOUNTAIN VIEW, Calif., Nov. 5, 2020 /PRNewswire/ --Cellecta, Inc. today announced the launch of its new RNA Spatial Profiling Service using NanoString's GeoMx Cancer Transcriptome Atlas (CTA) on the GeoMx Digital Spatial Profiler.

Key Points: 
  • MOUNTAIN VIEW, Calif., Nov. 5, 2020 /PRNewswire/ --Cellecta, Inc. today announced the launch of its new RNA Spatial Profiling Service using NanoString's GeoMx Cancer Transcriptome Atlas (CTA) on the GeoMx Digital Spatial Profiler.
  • As one of the few designated GeoMx Premier Access Site Partners worldwide, Cellecta offers immediate access to spatial transcriptomic analysis using the NanoString CTA and, upon release, to the GeoMx Whole Transcriptome Atlas.
  • "Their proven skills with RNA expression profiling and functional genomic analysis will be of great benefit to those seeking a greater understanding of tumor biology."
  • Further information about the company and its functional genomic products and services may be found at www.cellecta.com .